We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+69.67%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.08B
AUM Growth
+$395M
Cap. Flow
-$317M
Cap. Flow %
-15.21%
Top 10 Hldgs %
80.63%
Holding
43
New
6
Increased
4
Reduced
3
Closed
13

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$53.8M
2
BBOT
BridgeBio Oncology
BBOT
+$29.4M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$20.2M
4
MBX
MBX Biosciences
MBX
+$13M
5
AQST icon
Aquestive Therapeutics
AQST
+$11.3M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$197M
2
ITOS
iTeos Therapeutics
ITOS
+$107M
3
JANX icon
Janux Therapeutics
JANX
+$34M
4
KURA icon
Kura Oncology
KURA
+$23.7M
5
AKRO
Akero Therapeutics
AKRO
+$23.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
2 Miscellaneous 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
1
Zymeworks
ZYME
$2.02B
$392M 18.83%
22,970,388
– –
ANAB icon
2
AnaptysBio
ANAB
$1.67B
$241M 11.58%
7,880,094
– –
QURE icon
3
uniQure
QURE
$3.38B
$233M 11.17%
3,988,971
– –
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$225M 10.79%
1,706,469
– –
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$179M 8.57%
4,288,120
– –
CRSP icon
6
CRISPR Therapeutics
CRSP
$5.58B
$90M 4.32%
1,389,276
– –
TNGX icon
7
Tango Therapeutics
TNGX
$3.94B
$89.3M 4.29%
10,630,736
– –
ORIC icon
8
Oric Pharmaceuticals
ORIC
$1.37B
$80.7M 3.87%
6,728,116
+5,110,048
+316% +$53.8M
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$78M 3.74%
3,447,156
-8,448,652
-71% -$197M
XNCR icon
10
Xencor
XNCR
$1.94B
$72.1M 3.46%
6,144,767
– –
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$57.7M 2.77%
1,667,119
+630,174
+61% +$20.2M
IMNM icon
12
Immunome
IMNM
$3.13B
$47.8M 2.29%
4,079,415
– –
ETON icon
13
Eton Pharmaceutcials
ETON
$1.71B
$44.1M 2.12%
2,030,544
– –
MBX
14
MBX Biosciences
MBX
$3.03B
$37.2M 1.78%
2,123,604
+973,810
+85% +$13M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.3B
$34.4M 1.65%
75,000
– –
RNAM
16
DELISTED
Avidity Biosciences
RNAM
$33.3M 1.6%
765,000
+265,000
+53% +$10.7M
BBOT
17
BridgeBio Oncology
BBOT
$701M
$32.7M 1.57%
+2,823,126
New +$29.4M
NGNE icon
18
Neurogene
NGNE
$732M
$22M 1.06%
1,271,342
– –
ALKS icon
19
Alkermes
ALKS
$7.95B
$15M 0.72%
500,000
– –
AQST icon
20
Aquestive Therapeutics
AQST
$630M
$14.7M 0.7%
+2,625,000
New +$11.3M
MTSR
21
DELISTED
Metsera Inc
MTSR
$14.2M 0.68%
271,529
– –
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$13.3M 0.64%
+550,000
New +$9.78M
PRME icon
23
Prime Medicine
PRME
$655M
$8.55M 0.41%
+1,543,326
New +$6.27M
ATRA icon
24
Atara Biotherapeutics
ATRA
$92.3M
$8.21M 0.39%
573,183
– –
KURA icon
25
Kura Oncology
KURA
$1.13B
$7.72M 0.37%
872,500
-3,327,500
-79% -$23.7M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2025 Portfolio in Review

As of Q3 2025, EcoR1 Capital held 43 positions worth $2.08B, up 23% from $1.69B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

EcoR1 Capital withdrew a net $317M in Q3 2025, closing 13 positions and reducing 3 holdings. Its most notable exit was iTeos Therapeutics, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in BridgeBio Oncology worth $32.7M.

  • EcoR1 Capital's largest Q3 2025 buy was BridgeBio Oncology: 2,823,126 shares worth $32.7M.
  • EcoR1 Capital added most to Oric Pharmaceuticals in Q3 2025, an estimated $53.8M increase.
  • EcoR1 Capital's biggest Q3 2025 reduction was Apellis Pharmaceuticals, cutting an estimated $197M.
  • EcoR1 Capital fully exited iTeos Therapeutics in Q3 2025, selling an estimated $107M.
  • EcoR1 Capital's ten largest holdings make up 81% of its $2.08B portfolio in Q3 2025.
  • EcoR1 Capital opened 6 new positions and closed 13 in Q3 2025.
  • EcoR1 Capital's portfolio value rose 23% quarter-over-quarter to $2.08B.

Based on EcoR1 Capital's 13F filing for Q3 2025, filed 14 Nov 2025.